Pfizer catapulted itself into the vaccine big leagues in 2009 by merging with Wyeth, and continued demand for Prevnar 13 has seen it consolidate its position. Analysts predict its sales could dwarf other vaccines--hitting $6.7 billion in 2018--but recent quarters suggest it will be a bumpy ride.
Novartis nabbed EU approval of Bexsero, a meningitis B vaccine the company has been banking on to bolster its lagging vaccine unit.
Novartis has won European approval of Bexsero, its new meningitis B vaccine, which is central to the Big Pharma's drive to grow its big vaccine unit.
Novartis, still riding high on a European Medicine Agency committee backing of its meningitis vaccine Bexsero, confirmed more upbeat results from a study showing the shot offered broad protection to infants.
Novartis ($NVS) hit a key turning point with its vaccines division when a European Union committee backed the company's Bexsero meningitis shot.
Novartis' ($NVS) vaccine business is hanging in the balance, relying on the potential approval of a shot to protect against a meningitis-causing bacteria to keep the unit afloat.
Novartis ($NVS) is reporting its vaccine Bexsero stimulated an immune response against three strains of the meningococcus B bacterium. An approval would open the door to jabs that would combat the
A vaccine against meningococcal B disease, a devastating bacterial infection that is hard to diagnose and can kill in 24 hours, has come a step closer with infant Phase IIb data for Novartis' ($NVS)
Novartis appears to have made more progress in the battle against meningitis B. The Swiss drug giant says that its experimental vaccine Bexsero (a.k.a. 4CMenB) could protect against about 80 percent